Currently, results from phase 3 trials are lacking, trials including ADRIATIC and AdvanTIG 204 are currently evaluating anti–PD–(L)1, dual–ICIs, and ICI combined with anti–TIGIT antibody plus CCRT for LS–SCLC (119). This evidence concerns the gene TIGIT and small cell lung carcinoma.